Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. 1995

M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
Department of Retinoid Chemistry Research, Ligand Pharmaceuticals, Inc., San Diego, California 92121, USA.

Structural modifications of the retinoid X receptor (RXR) selective compound 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2- naphthyl)ethenyl]benzoic acid (LGD1069), which is currently in phase I/IIA clinical trials for cancer and dermatological indications, have resulted in the identification of increasingly potent retinoids with > 1000-fold selectivity for the RXRs. This paper describes the design and preparation of a series of RXR selective retinoids as well as the biological data obtained from cotransfection and competitive binding assays which were used to evaluate their potency and selectivity. The most potent and selective of the analogs is 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2- yl)cyclopropyl]nicotinic acid (12d; LG100268). This compound has proven useful for investigating RXR dependent biological pathways including the induction of programmed cell death (PCD) and transglutaminase (TGase) activity. Our studies indicate that the induction of PCD and TGase in human leukemic myeloid cells is dependent upon activation of RXR-mediated pathways.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D009525 Niacin A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties. Nicotinic Acid,3-Pyridinecarboxylic Acid,Enduracin,Induracin,Lithium Nicotinate,Niacin Aluminum Salt,Niacin Ammonium Salt,Niacin Calcium Salt,Niacin Cobalt (2+) Salt,Niacin Copper (2+) Salt,Niacin Hydrochloride,Niacin Iron (2+) Salt,Niacin Lithium Salt,Niacin Lithium Salt, Hemihydrate,Niacin Magnesium Salt,Niacin Manganese (2+) Salt,Niacin Potassium Salt,Niacin Sodium Salt,Niacin Tartrate,Niacin Tosylate,Niacin Zinc Salt,Nicamin,Nico-400,Nicobid,Nicocap,Nicolar,Nicotinate,Wampocap,3 Pyridinecarboxylic Acid,Aluminum Salt, Niacin,Hydrochloride, Niacin,Nico 400,Nico400,Nicotinate, Lithium,Potassium Salt, Niacin,Sodium Salt, Niacin,Tartrate, Niacin,Tosylate, Niacin
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D011503 Transglutaminases Transglutaminases catalyze cross-linking of proteins at a GLUTAMINE in one chain with LYSINE in another chain. They include keratinocyte transglutaminase (TGM1 or TGK), tissue transglutaminase (TGM2 or TGC), plasma transglutaminase involved with coagulation (FACTOR XIII and FACTOR XIIIa), hair follicle transglutaminase, and prostate transglutaminase. Although structures differ, they share an active site (YGQCW) and strict CALCIUM dependence. Glutaminyl-Peptide Gamma-Glutamyltransferases,Protein-Glutamine gamma-Glutamyltransferases,Transglutaminase,Gamma-Glutamyltransferases, Glutaminyl-Peptide,Glutaminyl Peptide Gamma Glutamyltransferases,Protein Glutamine gamma Glutamyltransferases,gamma-Glutamyltransferases, Protein-Glutamine
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077610 Bexarotene A rexinoid (an RXR-binding ligand), tetrahydronaphthalene derivative and RETINOID X RECEPTOR antagonist that is used in the treatment of CUTANEOUS T-CELL LYMPHOMA. 3-methyl-TTNEB,4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid,LG69 compound,LGD 1069,LGD-1069,LGD1069,Targretin
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012176 Retinoids A group of tetraterpenes, with four terpene units joined head-to-tail. Biologically active members of this class are used clinically in the treatment of severe cystic ACNE; PSORIASIS; and other disorders of keratinization. Retinoid
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
February 1999, Journal of medicinal chemistry,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
February 1999, Bioorganic & medicinal chemistry letters,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
October 2004, Molecular cancer therapeutics,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
April 1999, The New England journal of medicine,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
March 1996, Blood,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
July 1997, The Prostate,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
March 1996, Proceedings of the National Academy of Sciences of the United States of America,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
August 2001, The Journal of organic chemistry,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
April 2004, Journal of medicinal chemistry,
M F Boehm, and L Zhang, and L Zhi, and M R McClurg, and E Berger, and M Wagoner, and D E Mais, and C M Suto, and J A Davies, and R A Heyman
October 2017, Science signaling,
Copied contents to your clipboard!